Abiopharma

Agilon Health Investigation Continued: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of agilon health, inc. - AGL

New Form SCHEDULE 13G - InMed Pharmaceuticals Inc. Filed: 2026-01-20 AccNo: 0001535610-26-000009 Size: 9 KB

Ways to Use NotebookLM: Practical Ideas and Real‑World Use Cases

NASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

NASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

NASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

NASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

NASDAQ traded attribute type Financial_Status was changed. Previous value: Deficient. New value: Normal.

NASDAQ traded attribute type Financial_Status was changed. Previous value: Normal. New value: Deficient.

PULSENMORE (PLSM) was added to the list of traded instruments on TASE exchange

New Form SCHEDULE 13G - Biodexa Pharmaceuticals Plc Filed: 2026-01-20 AccNo: 0001535610-26-000008 Size: 9 KB

New Form 3 - AKANDA CORP. Filed: 2026-01-20 AccNo: 0001475597-26-000001 Size: 3 KB

New Form SCHEDULE 13G/A - Pennant Group, Inc. Filed: 2026-01-20 AccNo: 0001524408-26-000002 Size: 20 KB

Waters - Waters Corporation Schedules Fourth Quarter 2025 Earnings Conference Call

Waters Corporation Schedules Fourth Quarter 2025 Earnings Conference Call